Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26112465 | 0.85 | ADORA2A (0.42) | ADORA2AADORA1KDM4EHTTATM | |
| SCHEMBL31352821 | 0.79 | HCRTR1 (0.37) | EGFRATMJAK2 | |
| SCHEMBL31469351 | 0.79 | GSK3B (0.46) | EGFRKDM4EALDH1A1GAAERBB4 | |
| SCHEMBL26113555 | 0.79 | EGFR (0.48) | EGFRKDM4EALDH1A1GAAERBB4 | |
| SCHEMBL31469333 | 0.77 | EGFR (0.43) | EGFRKDM4EALDH1A1GAAERBB4 | |
| SCHEMBL31469253 | 0.76 | MAPT (0.52) | EGFRKDM4EALDH1A1GAAERBB4 | |
| SCHEMBL31469356 | 0.75 | MAPT (0.44) | EGFRKDM4EERBB4ERBB2MEN1 | |
| SCHEMBL26114206 | 0.72 | TSHR (0.53) | EGFRKDM4EERBB4ERBB2KDR | |
| SCHEMBL31469256 | 0.72 | ALDH1A1 (0.44) | EGFRKDM4EHTTATMALDH1A1 | |
| SCHEMBL26585005 | 0.72 | MAPT (0.52) | EGFRKDM4EALDH1A1GAAERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ADORA2A 3877/4885ADORA1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.